Drugs / Mana 312
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04679194 | Dec 2020 → Mar 2023 | acute myeloid leukemia | Mana Therapeutics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mana 312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04679194 ↗ |
| Route | Intravenous | “Mana 312 is administered intravenously (IV) within 30 minutes” NCT04679194 ↗ |